Wyatt Roth demonstrates that orally disintegrating tablets dissolve faster than swallowed tablets, making them more suitable for patients who have trouble swallowing. Members of a safety advisory group simulate a remote clinical assessment over a smartphone to explore patient care in the home. Dr. Bill Dirkes wears a device to monitor his vital signs as part of a demonstration of future clinical research technologies. The group also considers medication packaging design to ensure instructions are clear, blister packs aid adherence, and sustainability. Kevin Hudziak and Chris Hoyle test the usability of an electronic consent kit used in some of Lilly's studies.

1. Wyatt Roth, of Lilly's product design team, demonstrates the dissolution time of an orally disintegrating tablet
(ODT) versus a swallowed tablet. The ODTs are valuable for patients who have trouble swallowing, such as
children or patients with neurodegenerative disorders.

2. SAG members have fun exploring the possibility of receiving a clinical assessment over a smart phone in a
setting designed to simulate a patient’s home.

3. Dr. Bill Dirkes, of Sentral Clinical Research Services in Cincinnati, dons a wearable device to monitor his vital
signs and other key measures, as part of a demonstration exploring a future vision of clinical research care.

4. SAG members explore design considerations for packaging of medication—are the instructions easy to
understand, would a blister pack help patients keep track of an unusual dosing schedule, and is the packaging
environmentally sustainable?

5. Kevin Hudziak, an innovation lead at Lilly, and Chris Hoyle, of Elite Research Network, test the usability of an
eConsent kit that replicates one that is currently being used in select Lilly studies.